Today, with MD Anderson Cancer Center, we announce U.S. FDA clearance for the IND application of our TCR-NK #celltherapy in #MultipleMyeloma. This is the 2nd IND clearance for NY-ESO TCR/IL-15 NK, being developed in our #oncology product company, #Syena. More here: replay.bio/news/replay-an…

Our Executive Chairman, President, and Co-Founder AdrianWoolfson, will be attending the 8th CAR-TCR Summit today, 29 August until Friday 1 September in Boston. We look forward to attending the summit and to meeting fellow industry-leading executives. car-tcr-summit.com/?utm_source=di…

Today, we announce a new partnership between Syena, our oncology-focused product company and JURA Bio, Inc., to advance TCR- NK therapies in cancer. tinyurl.com/4un8zfm2

Our Executive Chairman, President, and Co-Founder AdrianWoolfson, will be attending ESMO - Eur. Oncology 2023 Congress this weekend in Madrid. We are looking forward to catching up with friends, collaborators, and colleagues. esmo.org/meeting-calend… #ESMO23

We recently sat down with our CMO Arun Balakumaran, to discuss the potential of T-Cell Receptor Natural Killer (TCR-NK) cell therapy for #sarcoma, following FDA clearance in June 2023 of the IND application of our investigational TCR-NK cell therapy. replay.bio/news/in-discus…

Congratulations to Katy Rezvani, M.D., Ph.D, M.D., Ph.D. on receiving the 2023 E.Donnall Thomas Lecture and Prize from ASH for her pioneering work investigating new approaches to harnessing the immune system against cancer. tinyurl.com/48fwh25k

Replay’s #Syena, signs two exclusive licensing & manufacturing agreements - with Miltenyi Biotec to support the development of a GMP-compliant TCR-NK #celltherapy and with NIH to develop a library of #TCR’s directed against multiple cancer neoantigens replay.bio/news

Wrapping up a wonderful year at @Replay by kicking off our #ReplayRewind series, recognizing the remarkable achievements of our team #Replay #Syena #Telaria #Eudora #Kaleibe #GenomicMedicine

Our Executive Chairman, President, and Co-Founder AdrianWoolfson has authored a commentary on #genomewriting and #genomedesign for #GENBiotechnology. liebertpub.com/doi/full/10.10…

Happy Holidays and wishing you a successful 2024!

Congratulations to Katy Rezvani, M.D., Ph.D on her Nature Medicine paper detailing the results of a Ph I/2 study demonstrating the safety, efficacy, and durability of responses of optimal donor-derived allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors.tinyurl.com/2s42zamz

Our Executive Chairman, President, and Co-Founder AdrianWoolfson will be one of the featured speakers at Genetic Engineering & Biotechnology News The State of #Cell and #Gene Therapy 2024 virtual summit today to discuss the rapidly evolving landscape of cell and gene therapy.

Yesterday was #WorldCancerDay, reimagining a world where cancer deaths are prevented and with equitable access to treatment. We continue to develop the next generation of treatments to overcome current scientific and clinical challenges. #WorldCancerDay #CloseTheCareGap

To celebrate the International Day of Women and Girls in Science, we are recognizing the vital role of women and girls in advancing science, technology, and innovation for a brighter healthier future, at #Replay and beyond. #WomenAndGirlsInScience #Inspiration #WomenInStem

Catch our Executive Chairman, President, and Co-Founder AdrianWoolfson, at the World Governments Summit 2024 in Dubai, an exciting gathering of governments, thought leaders, private sector leaders and international organizations. worldgovernmentsummit.org/events/2024 #WGS2024

We are pleased to announce that the first patient has been dosed in the Ph 1/2 study of NY-ESO-1/IL-15 NK, #Syena’s engineered TCR-NK cell therapy for relapsed/refractory multiple myeloma. replay.bio/news/replays-c… #genomicMedicine #genomeWriting #Oncology #Syena

Our Executive Chairman, President, and Co-Founder AdrianWoolfson and CEO, Lachlan MacKinnon, spoke with Precision Medicine Online to discuss how #Syena’s TCR-NK #cellTherapies could offer significant advantages over other cell-based immunotherapies. precisionmedicineonline.com/precision-onco…

Our CEO and Co-Founder, Lachlan MacKinnon along with #Syena Co-Founder Katy Rezvani, M.D., Ph.D, spoke on the panel “Bench to biotech: Successfully collaborating to translate therapies from academia into biotech” at the Alliance for Cancer Gene Therapy Summit in New York City last week.

Our Executive Chairman, President, and Co-Founder AdrianWoolfson and CEO, Lachlan MacKinnon join the BIOS podcast where they explore Replay’s history and speculate on the future of Replay, and #genomicMedicine. youtube.com/watch?v=To6u4L… #genomeWriting #Biotech

With MD Anderson Cancer Center, we announce U.S. FDA clearance for the IND application of our PRAME TCR/IL-15 NK #cellTherapy in #AML, #MDS and #multipleMyeloma developed by our #oncology product company #Syena. The phase 1/2 study is expected to commence in Q3 2024.replay.bio/news/replay-an…